The ongoing trial, LIBRETTO-531 (NCT04211337), is investigating the safety and efficacy of selpercatinib compared with standard treatment (cabozantinib or vandetanib) in MKI-naive patients with RET-mutant MTC that cannot be resected or has metastasised (90). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.